11/27
07:01 pm
rgnx
REGENXBIO (RGNX) Q3 2025 Earnings Call Transcript [Yahoo! Finance]
Low
Report
REGENXBIO (RGNX) Q3 2025 Earnings Call Transcript [Yahoo! Finance]
11/26
05:35 pm
rgnx
Regenxbio files $300M mixed shelf offering [Seeking Alpha]
Low
Report
Regenxbio files $300M mixed shelf offering [Seeking Alpha]
11/25
07:50 am
rgnx
REGENXBIO to Participate in Upcoming Investor Conference [Yahoo! Finance]
Low
Report
REGENXBIO to Participate in Upcoming Investor Conference [Yahoo! Finance]
11/25
07:05 am
rgnx
REGENXBIO to Participate in Upcoming Investor Conference
Medium
Report
REGENXBIO to Participate in Upcoming Investor Conference
11/24
02:05 am
rgnx
Medium
Report
11/20
08:07 am
rgnx
REGENXBIO (NASDAQ:RGNX) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $52.00 price target on the stock.
Low
Report
REGENXBIO (NASDAQ:RGNX) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $52.00 price target on the stock.
11/16
01:10 am
rgnx
11/9
07:23 am
rgnx
Earnings Update: REGENXBIO Inc. (NASDAQ:RGNX) Just Reported And Analysts Are Boosting Their Estimates [Yahoo! Finance]
Low
Report
Earnings Update: REGENXBIO Inc. (NASDAQ:RGNX) Just Reported And Analysts Are Boosting Their Estimates [Yahoo! Finance]
11/8
02:27 am
rgnx
REGENXBIO's Late-Stage Pipeline Momentum Strengthens After Q3 Earnings Beat [Seeking Alpha]
Low
Report
REGENXBIO's Late-Stage Pipeline Momentum Strengthens After Q3 Earnings Beat [Seeking Alpha]
11/7
03:02 pm
rgnx
REGENXBIO (NASDAQ:RGNX) had its price target raised by analysts at Royal Bank Of Canada from $17.00 to $19.00. They now have an "outperform" rating on the stock.
Low
Report
REGENXBIO (NASDAQ:RGNX) had its price target raised by analysts at Royal Bank Of Canada from $17.00 to $19.00. They now have an "outperform" rating on the stock.
11/6
04:18 pm
rgnx
REGENXBIO Inc. (RGNX) Q3 2025 Earnings Call Transcript [Seeking Alpha]
Medium
Report
REGENXBIO Inc. (RGNX) Q3 2025 Earnings Call Transcript [Seeking Alpha]
11/6
04:18 pm
rgnx
REGENXBIO plans top-line RGX-202 Duchenne data release in early Q2 2026 while advancing toward 2027 commercial launch [Seeking Alpha]
Medium
Report
REGENXBIO plans top-line RGX-202 Duchenne data release in early Q2 2026 while advancing toward 2027 commercial launch [Seeking Alpha]
11/6
08:06 am
rgnx
REGENXBIO Reports Third Quarter 2025 Financial Results and Operational Highlights [Yahoo! Finance]
Low
Report
REGENXBIO Reports Third Quarter 2025 Financial Results and Operational Highlights [Yahoo! Finance]
11/6
07:17 am
rgnx
Regenxbio GAAP EPS of -$1.20 beats by $0.14, revenue of $29.7M beats by $5.29M [Seeking Alpha]
Low
Report
Regenxbio GAAP EPS of -$1.20 beats by $0.14, revenue of $29.7M beats by $5.29M [Seeking Alpha]
11/6
07:05 am
rgnx
REGENXBIO Reports Third Quarter 2025 Financial Results and Operational Highlights
Medium
Report
REGENXBIO Reports Third Quarter 2025 Financial Results and Operational Highlights
10/30
07:05 am
rgnx
REGENXBIO Announces Completion of Pivotal Enrollment and Initiates Commercial Production in Duchenne Gene Therapy Program
Low
Report
REGENXBIO Announces Completion of Pivotal Enrollment and Initiates Commercial Production in Duchenne Gene Therapy Program
10/29
07:05 am
rgnx
REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2025 Financial Results and Operational Highlights
Medium
Report
REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2025 Financial Results and Operational Highlights
10/15
07:05 am
rgnx
REGENXBIO to Participate in Upcoming Investor Conferences
Medium
Report
REGENXBIO to Participate in Upcoming Investor Conferences
10/9
07:26 am
rgnx
REGENXBIO Announces Presentation at the American Academy of Ophthalmology 2025 Annual Meeting [Yahoo! Finance]
Low
Report
REGENXBIO Announces Presentation at the American Academy of Ophthalmology 2025 Annual Meeting [Yahoo! Finance]
10/9
07:05 am
rgnx
REGENXBIO Announces Presentation at the American Academy of Ophthalmology 2025 Annual Meeting
Low
Report
REGENXBIO Announces Presentation at the American Academy of Ophthalmology 2025 Annual Meeting
10/7
08:10 am
rgnx
REGENXBIO (NASDAQ:RGNX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $34.00 price target on the stock.
Medium
Report
REGENXBIO (NASDAQ:RGNX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $34.00 price target on the stock.
10/6
07:45 am
rgnx
REGENXBIO Announces Completion of Enrollment in Pivotal Trials of Subretinal Surabgene Lomparvovec for Wet AMD [Yahoo! Finance]
Low
Report
REGENXBIO Announces Completion of Enrollment in Pivotal Trials of Subretinal Surabgene Lomparvovec for Wet AMD [Yahoo! Finance]
10/6
07:05 am
rgnx
REGENXBIO Announces Completion of Enrollment in Pivotal Trials of Subretinal Surabgene Lomparvovec for Wet AMD
Low
Report
REGENXBIO Announces Completion of Enrollment in Pivotal Trials of Subretinal Surabgene Lomparvovec for Wet AMD
9/29
07:16 am
rgnx
REGENXBIO Announces Presentation at the World Muscle Society [Yahoo! Finance]
Low
Report
REGENXBIO Announces Presentation at the World Muscle Society [Yahoo! Finance]
9/29
07:05 am
rgnx
REGENXBIO Announces Presentation at the World Muscle Society
Low
Report
REGENXBIO Announces Presentation at the World Muscle Society